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ABSTRACT
Treatment with paracetamol, ketorolac or 
etoricoxib did not hinder alveolar bone healing: 
a histometric study in rats
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Prostaglandins control osteoblastic and osteoclastic function under physiological or pathological conditions and are important modulators of the bone healing process. The 
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consequently prostaglandins synthesis. Experimental and clinical evidence has indicated a 
risk for reparative bone formation related to the use of non-selective (COX-1 and COX-2) 
and COX-2 selective NSAIDs. Ketorolac is a non-selective NSAID which, at low doses, has 
a preferential COX-1 inhibitory effect and etoricoxib is a new selective COX-2 inhibitor. 
Although literature data have suggested that ketorolac can interfere negatively with long 
bone fracture healing, there seems to be no study associating etoricoxib with reparative 
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present study was to investigate whether paracetamol, ketorolac and etoricoxib can hinder 
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as experimental model. Material and Methods: The degree of new bone formation inside 
the alveolar socket was estimated two weeks after tooth extraction by a differential point-
counting method, using an optical microscopy with a digital camera for image capture 
and histometry software. Differences between groups were analyzed by ANOVA after 
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fraction of bone trabeculae formed inside the alveolar socket.
Key words: Bone regeneration. Paracetamol. Ketorolac. Cyclooxygenase 1. Cyclooxygenase 
2. Cyclooxygenase 1 inhibitors. Cyclooxygenase 2 inhibitors.
INTRODUCTION
The cyclooxygenase enzymes COX-1 and COX-
2 catalyze the conversion of arachidonic acid to 
prostaglandins, which, in addition to a variety of 
physiological functions, are also involved in several 
pathological processes. The non-steroidal anti-
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and consequently prostaglandin synthesis24. A wide 
array of NSAIDs is currently available, notably the 
conventional NSAIDs, which inhibit non-selectively 
both enzymes COX-1 and COX-2, and a new class 
of selective COX-2 inhibitors.
The skeleton is abundantly supplied with 
prostaglandins, mainly PGE2, which modulate 
osteoblastic and osteoclastic function under 
physiological or pathological conditions. The anabolic 
effect of PGE2 		'
mechanical forces and in the healing process24. Not 
surprisingly, considerable experimental and clinical 
evidence has indicated a risk for reparative bone 
formation related to the use of selective and non-
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selective NSAIDs in the orthopedic clinic, although 
an absence of this deleterious effect has also been 
reported16.
Even though the NSAIDs are among the most 
commonly used drugs for management of acute 
and chronic pain in clinical dentistry23, very few 
studies have been conducted to assess their effects 
on alveolar bone. A small number of experimental 
investigations have suggested the deleterious effect 
of conventional NSAIDs on alveolar bone healing2,30 
and some clinical assessments have reported no 
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following administration of this kind of drug3,4,17.
Ketorolac is a conventional (non-selective) 
NSAID which, in low doses, has a preferential COX-1 
inhibitory effect29 while etoricoxib is a new selective 
COX-2 inhibitor21,26. Literature data have suggested 
that ketorolac can interfere negatively with new 
bone formation in different experimental models 
(femur fracture healing, spinal fusion and ulna 
osteotomy in rats and rabbits)11,15 in opposition to 
one report stating that ketorolac does not interfere 
with tibia fracture repair in mouse18. To the best 
of our knowledge, there are no reports about the 
effects of etoricoxib on bone repair, except for few 
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periodontitis.
Since the 1970s, paracetamol/acetaminophen 
has become one of the most popular and widely 
used drugs in the world for treatment of pain and 
fever6*
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in clinical dentistry20. Although it is generally 
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drug, paracetamol seems capable of inhibiting COX-
3	"				12. In spite of this, 
treatment of rats with paracetamol did not hinder 
femur fracture healing5.
The purpose of the present study was to 
investigate whether paracetamol, ketorolac or 
etoricoxib may have a detrimental effect on 
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rat extraction socket with newly formed bone as 
experimental model.
MATERIAL AND METHODS
Male Wistar rats (about 250 g initial body 
weight) were anaesthetized with a solution of 
ketamine hydrochloride (Ketamina Agener, União 
Química Farmacêutica Nacional S/A, Embu-Guaçu, 
SP, Brazil; 75 mg/kg) and xylazine (Dopaser, 
Laboratórios Calier S/A, Barcelona, Spain; 10 mg/
kg) administered intraperitoneally, and had the 
upper right incisors extracted and the wounds 
sutured with mononylon 4-0 (Ethicon, Johnson 
& Johnson, São José dos Campos, SP, Brazil). A 
single dose (0.2 mL per rat, intramuscularly) of 
a polyvalent veterinary antibiotic (Pentabiótico 
Veterinário, Wyeth, São Bernardo do Campo, SP, 
Brazil) was administered immediately after surgery 
and 5 days later.
Treated rats received oral doses of 1 mL aqueous 
solution of paracetamol (Paracetamol; Biossintética 
Farmacêutica Ltda, São Paulo, SP, Brazil - 80 mg/
kg/rat/day), ketorolac (Toragesic; Sigma Pharma, 
Hortolândia, SP, Brasil – 4 mg/kg/day) or etoricoxib 
(Arcoxia; Merck do Brasil, São Paulo, SP, Brazil; 
10 mg/kg/day) administered by gavage from the 
day of surgery until death, 2 weeks later. Control 
rats received tap water (1 mL/day by gavage). 
The animals were housed under climate-controlled 
environment (12 h light/12 h dark, 20-24°C) with 
free access to standard laboratory chow and tap 
water. All procedures were conducted in compliance 
with ethical principles for animal research, as 
approved by institutional guidelines (Protocol CETEA 
117/2006).
The animals were killed with an intraperitoneal 
overdose of sodium pentobarbital 2 weeks 
postoperatively and their heads were immersed 
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processed for paraffin embedding. Semi-serial 
longitudinal 6-μm-thick sections of the hemi-
maxillae containing the alveolar sockets were cut 
at 60-μm intervals and stained with hematoxylin 
and eosin.
For histometric analysis, the degree of new bone 
formation inside the alveolar socket was estimated 
by a differential point-counting method, using an 
optical microscopy (Zeiss Axiostar Plus; Carl Zeiss, 
Jena, Germany) with a digital camera for image 
capture (Zeiss Axiocam IC; Carl Zeiss) and a public 
domain histometry software (Image J, version 1.38, 
Mental Health Institute, Bethesda, Maryland, USA). 
The healing process, which in this phase consists 
of a gradual replacement of connective tissue 
by bone trabeculae, was estimated by new bone 
volume fraction (% bone trabeculae relative to 
bone trabeculae plus connective tissue). A total of 
1100-1300 points were counted in 8-9 histological 
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the percentage of points lying on bone trabeculae 
being proportional to their volume density. The 
measurements were standardized in the cervical and 
apical alveolar thirds, in order to avoid interference 
of regional differences in the rate of bone healing. 
Differences between groups were analyzed by 
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(Kolmogorov-Smirnov normality test, p>0.10).
RESULTS
Histological examination showed the alveolar 
socket of control rats (Figure 1A) occupied by 
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connective tissue and a network of delicate bone 
trabeculae lined with osteoblasts, forming from 
the inner surfaces of the alveolar walls. Blood clot 
remnants were still observed, mainly in the central 
region of the apical and middle alveolar thirds. 
In rats treated with paracetamol (Figure 1B), 
ketorolac (Figure 1C) or etoricoxib (Figure 1D), the 
bone healing process did not show any noticeable 
difference as compared to the controls.
Histometric data confirmed histological 
observation that neither paracetamol nor ketorolac 
or etoricoxib affected significantly the volume 
fraction of bone trabeculae forming inside the 
alveolar socket (Figure 2).
DISCUSSION
In the present study, the intra-alveolar healing 
process in the control and treated groups closely 
resembled literature data. Briefly, after tooth 
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is progressively invaded by capillary sprouting and 
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remnants; in the sequence, the coagulum is 
gradually absorbed and replaced by immature 
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and blood vessels decreases and the osteoblasts 
become evident. The osteoblasts initially synthesize 
an immature bone matrix that is further mineralized 
by calcium deposition as hydroxyapatite crystals. 
New alveolar bone formation takes place from the 
apical and lateral walls towards the center, and 
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dental socket by trabecular bone7,8. It has been 
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bone formation13 and the maximum mineral bone 
density8 take place by the end of the 2nd week after 
tooth extraction, which was the period elected for 
bone healing measurement in the present study. 
In the present study, neither NSAIDs, ketorolac 
Figure 1- Rat alveolar sockets at 2 weeks after tooth 
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) forming from the inner 
surface of the lateral alveolar wall (LAW) in a control rat (A) 
and in rats treated with paracetamol (B), ketorolac (C) and 
etoricoxib (D); blood clot remnant (BC) interposed among 
new bone trabeculae in a ketorolac-treated rat
Figure 2- Percent of new bone trabeculae (meanstandard 
error of mean) inside the alveolar socket, 2 weeks after 
tooth extraction, in control (CON) rats and in rats treated 
with ketorolac (KET), etoricoxib (ETO) and paracetamol 
(PAR)
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and etoricoxib, interfered with rat alveolar bone 
repair two weeks after tooth extraction.
Studies regarding the effect of COX inhibition 
on alveolar bone healing are scarce and refer only 
to non-selective NSAIDs10. A histological study 
was conducted to investigate the effects of long-
term treatment with aspirin cones placed in the 
extraction sockets of dogs2. The authors reported 
delayed alveolar bone formation in the 2-week 
samples, but not after long-term treatment, and 
admitted limitations in the experimental model that 
allowed the drug to stay in the sockets only for 2-3 
days. In rats, short-term treatment (4 days) with 
diclofenac also delayed alveolar socket healing30. 
Clinical investigations are equally rare and pertain 
to short-term administration of NSAIDs to control 
edema and pain after removal of impacted third 
molars. Based on clinical postoperative assessment, 
some surgeons have reported no significant 
difference in the rate of bone healing following 
administration of ibuprofen17 aspirin, diclofenac4 
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inhibition of COX-1 and COX-2 by the conventional 
NSAIDs (indomethacin, ibuprofen, naproxen, 
ketorolac) can interfere negatively with long bone 
fracture healing and spinal fusion rate, although 
an absence of this deleterious effect has also been 
reported. Many experimental and clinical studies 
were also conducted to verify the effects of selective 
COX-2 NSAIDs and, despite the importance of COX-
2 and PGE2 for bone formation, the results are also 
controversial. In addition to evidence showing that 
the coxibs (rofecoxib, celecoxib and parecoxib) 
inhibit long bone repair in rats and rabbits, there 
are some reports stating that they do not interfere 
with fracture repair and spinal fusion rate, both in 
rodents and humans16.
Factors such as dosage and duration of treatment, 
as well as age, intra- and inter-species differences 
regarding sensitivity to drugs, compensatory 
local and systemic factors, pharmacokinetics of 
drugs in laboratory animals compared to humans 
and rate of bone remodeling9,18,24 have been 
considered responsible for the controversies in 
the experimental results about the effects of COX 
inhibitors on bone healing.
In rats, ketorolac used in small doses is 
considered a preferential COX-1 inhibitor (3 mg/
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inhibition of COX-2 activity)28, and can hinder 
femur fracture healing11. A recent in vitro study 
investigated the effect of ketorolac (among seven 
COX-1 and COX-2 inhibitors) on the marrow stem cell 
(MSC) potential for proliferation and differentiation 
towards the osteogenic and chondrogenic lineages. 
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MSC proliferation and osteogenic differentiation, 
some of them (mostly ketorolac) inhibited bone 
formation via blockage of MSC chondrogenic 
differentiation, which is an important intermediate 
phase in endochondral bone formation, such as in 
bone fracture healing22.
Etoricoxib is a selective COX-2 inhibitor (can 
block COX-2 activity 106 times28 or 344 times21 
more than COX-1 activity). In the same dose 
as that used in the present study, it can control 
hiperalgesia26 and reduce bone loss in periodontal 
disease1, in rats. In 2008, the Brazilian Agency 
of Sanitary Surveillance (ANVISA) suspended 
commercialization of 120 mg pills of etoricoxib, 
but allowed the sale of 60 and 90 mg pills provided 
the retention of medical prescription and inclusion 
of adverse effects warning in the bulla were done. 
Thus, remains the interest of the present study 
regarding long-term use of this drug for controlling 
chronic pain associated to musculoskeletal disorders 
and rheumatoid diseases as well as an experimental 
selective COX-2 inhibitor.
Paracetamol is a potent analgesic and antipyretic 
with a central mechanism of action still not 
completely understood. It has been claimed that 
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inhibition of peripheral prostanoids, presenting thus 
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However, a recent study carried out with human 
volunteers showed that paracetamol promotes more 
than 80% inhibition of peripheral COX-2, which is 
comparable to selective NSAIDs14.
Studies carried out in the late 1990s revealed a 
second peak of COX-2 occurring in the resolution 
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that this COX-2 has a reduced sensibility to 
NSAIDs but is highly sensitive to inhibition with 
paracetamol27. Inhibition of this late-appearing 
COX-2 with NSAIDs delayed resolution of the 
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early phases, but may contribute to resolution of 
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prostaglandins produced by activation of COX-2 are 
important factors that mediate resolution of the 
	'25.
All things considered, it could be supposed 
that paracetamol, inhibiting locally the late-
appearing COX-2, would delay the resolution of the 
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and hinder the subsequent bone healing. However, 
the supposed detrimental effect of paracetamol 
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present study.
A dose of paracetamol (80 mg/kg/day) compatible 
to human therapy and in the range of investigations 
carried out in laboratory animals was used in the 
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present study. Experimental studies dealing with 
the analgesic effect of paracetamol have employed 
a single dose (acute treatment) of 850 mg/kg19 and 
investigations about its effect on the healing of soft 
and mineralized tissues have used dosages of 60 
to 300 mg/kg/day, for up to 14 days (prolonged 
treatment)5. In the same way as observed in the 
present study, treatment of rats with paracetamol/
acetaminophen (60 or 300 mg/kg/day for 10 days) 
had no negative effect on femur fracture healing, 
as observed 8 weeks later by radiographic and 
histological examination as well as by mechanical 
testing. It is worth mentioning, however, that no 
assessment was made immediately after treatment 
completion5. Acetaminophen administered in 
standard concentrations in the food at an average 
dosage of 60 mg/kg/day during 14 days also had 
no detrimental effect on the healing of rat patellar 
tendon8.
CONCLUSION
Histometric data showed that prolonged 
treatment (2 weeks) with ketorolac (exerting 
a preferential COX-1 inhibition), etoricoxib (a 
selective COX-2 inhibitor) or paracetamol (a weak 
NSAID supposedly capable of inhibiting COX-2 
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negatively with alveolar bone healing, in rats.
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